{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:15:50Z","timestamp":1790237750731,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["20K17418"],"award-info":[{"award-number":["20K17418"]}]},{"name":"The Cardiovascular Research Fund, Tokyo, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    HLA-B*52 is an established genetic factor in Takayasu arteritis (TAK). Recently, single nucleotide polymorphisms (SNPs) in\n                    <jats:italic>IL12B<\/jats:italic>\n                    (rs6871626) and\n                    <jats:italic>LILRA3<\/jats:italic>\n                    (rs103294) were newly identified as non-HLA susceptibility loci in TAK. Here, we examined how these SNPs contribute to clinical characteristics and vascular damage in TAK. We retrospectively reviewed the medical records of 99 TAK patients enrolled in our previous genome-wide association study, and whose genotypes for\n                    <jats:italic>IL12B<\/jats:italic>\n                    rs6871626,\n                    <jats:italic>LILRA3<\/jats:italic>\n                    rs103294, and HLA-B*52 were available. Incidence of aortic regurgitation (AR) was significantly associated with the A allele (risk allele) of\n                    <jats:italic>IL12B<\/jats:italic>\n                    rs6871626 (CC 42%, AC 61%, AA 81%; p\u2009=\u20090.0052; odds ratio [OR] 2.45), as well as with the incidence of hypertension (p\u2009=\u20090.049; OR 1.82) and the proportion of patients who underwent aortic valve replacement (p\u2009=\u20090.023; OR 3.64). Regarding vascular damage, there was positive correlation between the Takayasu Arteritis Damage Score and the A allele of\n                    <jats:italic>IL12B<\/jats:italic>\n                    rs6871626 (CC 3.42\u2009\u00b1\u20092.71, AC 4.06\u2009\u00b1\u20093.25, AA 6.00\u2009\u00b1\u20092.81; p\u2009=\u20090.0035; \u03b2\u2009=\u20091.35) and between the Vasculitis Damage Index and the A allele (CC 3.47\u2009\u00b1\u20091.98, AC 4.33\u2009\u00b1\u20092.40, AA 5.37\u2009\u00b1\u20092.22; p\u2009=\u20090.0054; \u03b2\u2009=\u20090.96). Contrarily, no correlation was found between\n                    <jats:italic>LILRA3<\/jats:italic>\n                    rs103294 and vascular damage. In the present study,\n                    <jats:italic>IL12B<\/jats:italic>\n                    rs6871626 was associated with vascular damage in TAK, whereas\n                    <jats:italic>LILRA3<\/jats:italic>\n                    rs103294 was not. Genotyping of\n                    <jats:italic>IL12B<\/jats:italic>\n                    rs6871626 may help to identify patients at risk of disease progression.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-93213-9","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T06:05:24Z","timestamp":1625119524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A susceptibility locus in the IL12B but not LILRA3 region is associated with vascular damage in Takayasu arteritis"],"prefix":"10.1038","volume":"11","author":[{"given":"Keiichiro","family":"Kadoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kitagori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Akizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"issue":"7","key":"93213_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nrrheum.2010.82","volume":"6","author":"JC Mason","year":"2010","unstructured":"Mason, J. C. Takayasu arteritis\u2014Advances in diagnosis and management. Nat. Rev. Rheumatol. 6(7), 406\u2013415 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"93213_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11926-020-00948-x","volume":"22","author":"R Watanabe","year":"2020","unstructured":"Watanabe, R., Berry, G. J., Liang, D. H., Goronzy, J. J. & Weyand, C. M. Pathogenesis of giant cell arteritis and Takayasu arteritis-similarities and differences. Curr. Rheumatol. Rep. 22(10), 68 (2020).","journal-title":"Curr. Rheumatol. Rep."},{"issue":"3","key":"93213_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/1756-185X.12309","volume":"17","author":"C Terao","year":"2014","unstructured":"Terao, C., Yoshifuji, H. & Mimori, T. Recent advances in Takayasu arteritis. Int. J. Rheum. Dis. 17(3), 238\u2013247 (2014).","journal-title":"Int. J. Rheum. Dis."},{"issue":"2","key":"93213_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajhg.2013.05.024","volume":"93","author":"C Terao","year":"2013","unstructured":"Terao, C. et al. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am. J. Hum. Genet. 93(2), 289\u2013297 (2013).","journal-title":"Am. J. Hum. Genet."},{"issue":"51","key":"93213_CR5","doi-asserted-by":"publisher","first-page":"13045","DOI":"10.1073\/pnas.1808850115","volume":"115","author":"C Terao","year":"2018","unstructured":"Terao, C. et al. Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis. Proc. Natl. Acad. Sci. U.S.A. 115(51), 13045\u201313050 (2018).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"93213_CR6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s00380-015-0661-5","volume":"31","author":"T Matsumura","year":"2016","unstructured":"Matsumura, T. et al. A novel susceptibility locus for Takayasu arteritis in the IL12B region can be a genetic marker of disease severity. Heart Vessels 31(6), 1016\u20131019 (2016).","journal-title":"Heart Vessels"},{"issue":"11","key":"93213_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/jhg.2015.64","volume":"60","author":"K Hirayasu","year":"2015","unstructured":"Hirayasu, K. & Arase, H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J. Hum. Genet. 60(11), 703\u2013708 (2015).","journal-title":"J. Hum. Genet."},{"key":"93213_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41232-020-00119-6","volume":"40","author":"H Yoshifuji","year":"2020","unstructured":"Yoshifuji, H. & Terao, C. Roles of cytotoxic lymphocytes and MIC\/LILR families in pathophysiology of Takayasu arteritis. Inflamm. Regen. 40, 9 (2020).","journal-title":"Inflamm. Regen."},{"issue":"4","key":"93213_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.semarthrit.2020.04.003","volume":"50","author":"S Kaymaz-Tahra","year":"2020","unstructured":"Kaymaz-Tahra, S., Alibaz-Oner, F. & Direskeneli, H. Assessment of damage in Takayasu\u2019s arteritis. Semin. Arthritis Rheum. 50(4), 586\u2013591 (2020).","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"93213_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3899\/jrheum.131117","volume":"41","author":"R Goel","year":"2014","unstructured":"Goel, R. et al. Childhood-onset Takayasu arteritis\u2014Experience from a tertiary care center in South India. J. Rheumatol. 41(6), 1183\u20131189 (2014).","journal-title":"J. Rheumatol."},{"issue":"2","key":"93213_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley, A. R. et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 40(2), 371\u2013380 (1997).","journal-title":"Arthritis Rheum."},{"issue":"7","key":"93213_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/rheumatology\/kev366","volume":"55","author":"D Nakagomi","year":"2016","unstructured":"Nakagomi, D. & Jayne, D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford) 55(7), 1159\u20131171 (2016).","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"93213_CR13","doi-asserted-by":"publisher","first-page":"15979","DOI":"10.1038\/s41598-018-34395-7","volume":"8","author":"E Tombetti","year":"2018","unstructured":"Tombetti, E. et al. Novel angiographic scores for evaluation of large vessel vasculitis. Sci. Rep. 8(1), 15979 (2018).","journal-title":"Sci. Rep."},{"issue":"8","key":"93213_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ni.2366","volume":"13","author":"DA Vignali","year":"2012","unstructured":"Vignali, D. A. & Kuchroo, V. K. IL-12 family cytokines: Immunological playmakers. Nat. Immunol. 13(8), 722\u2013728 (2012).","journal-title":"Nat. Immunol."},{"issue":"1","key":"93213_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.it.2006.11.002","volume":"28","author":"AM Cooper","year":"2007","unstructured":"Cooper, A. M. & Khader, S. A. IL-12p40: An inherently agonistic cytokine. Trends Immunol. 28(1), 33\u201338 (2007).","journal-title":"Trends Immunol."},{"issue":"2","key":"93213_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2249.2004.02613.x","volume":"138","author":"NK Tripathy","year":"2004","unstructured":"Tripathy, N. K., Chauhan, S. K. & Nityanand, S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu\u2019s arteritis. Clin. Exp. Immunol. 138(2), 369\u2013374 (2004).","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"93213_CR17","first-page":"2361","volume":"32","author":"DK Verma","year":"2005","unstructured":"Verma, D. K., Tripathy, N. K., Verma, N. S. & Tiwari, S. Interleukin 12 in Takayasu\u2019s arteritis: Plasma concentrations and relationship with disease activity. J. Rheumatol. 32(12), 2361\u20132363 (2005).","journal-title":"J. Rheumatol."},{"issue":"5","key":"93213_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","volume":"45","author":"MC Park","year":"2006","unstructured":"Park, M. C., Lee, S. W., Park, Y. B. & Lee, S. K. Serum cytokine profiles and their correlations with disease activity in Takayasu\u2019s arteritis. Rheumatology (Oxford) 45(5), 545\u2013548 (2006).","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"93213_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jjcc.2016.10.016","volume":"70","author":"N Tamura","year":"2017","unstructured":"Tamura, N. et al. Profiles of serum cytokine levels in Takayasu arteritis patients: Potential utility as biomarkers for monitoring disease activity. J. Cardiol. 70(3), 278\u2013285 (2017).","journal-title":"J. Cardiol."},{"issue":"2 Suppl 89","key":"93213_CR20","first-page":"32","volume":"33","author":"F Alibaz-Oner","year":"2015","unstructured":"Alibaz-Oner, F., Yent\u00fcr, S. P., Saruhan-Direskeneli, G. & Direskeneli, H. Serum cytokine profiles in Takayasu\u2019s arteritis: Search for biomarkers. Clin. Exp. Rheumatol. 33(2 Suppl 89), 32\u201335 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"93213_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/art.39037","volume":"67","author":"D Saadoun","year":"2015","unstructured":"Saadoun, D. et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 67(5), 1353\u20131360 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"93213_CR22","first-page":"7841718","volume":"2016","author":"DP Misra","year":"2016","unstructured":"Misra, D. P., Chaurasia, S. & Misra, R. Increased circulating Th17 cells, serum IL-17A, and IL-23 in Takayasu arteritis. Autoimmune Dis. 2016, 7841718 (2016).","journal-title":"Autoimmune Dis."},{"issue":"1","key":"93213_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-017-1408-8","volume":"19","author":"T Nakajima","year":"2017","unstructured":"Nakajima, T. et al. A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. Arthritis Res. Ther. 19(1), 197 (2017).","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"93213_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/03009742.2015.1060521","volume":"45","author":"C Terao","year":"2016","unstructured":"Terao, C. et al. Ustekinumab as a therapeutic option for Takayasu arteritis: From genetic findings to clinical application. Scand. J. Rheumatol. 45(1), 80\u201382 (2016).","journal-title":"Scand. J. Rheumatol."},{"key":"93213_CR25","first-page":"1","volume":"31","author":"Y Gon","year":"2020","unstructured":"Gon, Y. et al. Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab. Mod. Rheumatol. 31, 1\u20136 (2020).","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"93213_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/ng.764","volume":"43","author":"CA Anderson","year":"2011","unstructured":"Anderson, C. A. et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43(3), 246\u2013252 (2011).","journal-title":"Nat. Genet."},{"issue":"7422","key":"93213_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491(7422), 119\u2013124 (2012).","journal-title":"Nature"},{"issue":"7","key":"93213_CR28","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","volume":"45","author":"A Cortes","year":"2013","unstructured":"Cortes, A. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat. Genet. 45(7), 730\u2013738 (2013).","journal-title":"Nat. Genet."},{"issue":"8","key":"93213_CR29","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/art.39157","volume":"67","author":"C Terao","year":"2015","unstructured":"Terao, C. et al. Takayasu arteritis and ulcerative colitis: High rate of co-occurrence and genetic overlap. Arthritis Rheumatol. 67(8), 2226\u20132232 (2015).","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"93213_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/14397595.2013.854045","volume":"24","author":"R Watanabe","year":"2014","unstructured":"Watanabe, R. et al. Ulcerative colitis is not a rare complication of Takayasu arteritis. Mod. Rheumatol. 24(2), 372\u2013373 (2014).","journal-title":"Mod. Rheumatol."},{"issue":"13","key":"93213_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381(13), 1201\u20131214 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"93213_CR32","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan, B. G. et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N. Engl. J. Med. 375(20), 1946\u20131960 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"93213_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.gene.6364187","volume":"6","author":"S Koch","year":"2005","unstructured":"Koch, S. et al. Association of multiple sclerosis with ILT6 deficiency. Genes Immun. 6(5), 445\u2013447 (2005).","journal-title":"Genes Immun."},{"issue":"6","key":"93213_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/gene.2009.34","volume":"10","author":"D Ord\u00f3\u00f1ez","year":"2009","unstructured":"Ord\u00f3\u00f1ez, D. et al. Multiple sclerosis associates with LILRA3 deletion in Spanish patients. Genes Immun. 10(6), 579\u2013585 (2009).","journal-title":"Genes Immun."},{"issue":"10","key":"93213_CR35","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1002\/art.24804","volume":"60","author":"G Kabalak","year":"2009","unstructured":"Kabalak, G. et al. Association of immunoglobulin-like transcript 6 deficiency with Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 60(10), 2923\u20132925 (2009).","journal-title":"Arthritis Rheum."},{"issue":"11","key":"93213_CR36","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1136\/annrheumdis-2013-204441","volume":"74","author":"Y Du","year":"2015","unstructured":"Du, Y. et al. Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 74(11), 2070\u20132075 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"93213_CR37","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/art.38308","volume":"66","author":"Y Du","year":"2014","unstructured":"Du, Y. et al. Contribution of functional LILRA3, but not nonfunctional LILRA3, to sex bias in susceptibility and severity of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 66(4), 822\u2013830 (2014).","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"93213_CR38","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.1780330811","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend, W. P. et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 33(8), 1129\u20131134 (1990).","journal-title":"Arthritis Rheum."},{"issue":"2","key":"93213_CR39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1253\/circj.CJ-88-0007","volume":"75","author":"JCS Joint Working Group","year":"2011","unstructured":"JCS Joint Working Group. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ. J. 75(2), 474\u2013503 (2011).","journal-title":"Japanese Circulation Society. Circ. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93213-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93213-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:40:32Z","timestamp":1670046032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93213-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93213"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93213-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"25 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). The above-mentioned pharmaceutical companies were not involved in the study design, data collection and analysis, manuscript writing, and manuscript submission. RW received speaker fees from Mitsubishi Tanabe Pharma, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Eli Lilly, Bristol-Myers Squibb, and Janssen. KK received research grants from GSK. KMurakami received speaking fees and\/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co. Ltd, Daiichi Sankyo Co. Ltd., and Astellas Pharma Inc. MH received a research grant and\/or speaker fees from Bristol-Myers, Eisai, Ely Lilly, Mitsubishi Tanabe Pharma. MT received research grants and\/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., and Taisho Pharma Co., Ltd. KO received research grants and\/or speaker fees from Abbvie, Actelion, Asahikasei Pharma, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, JB, Mitsubishi Tanabe, Nippon Kayaku, Nippon Shinyaku, Novartis, Sanofi, and Takeda. AM received speaking fees and\/or research grants from Chugai Pharmaceutical Co. Ltd. HY received lecture fees from Chugai and has been on the advisory board for a clinical trial conducted by Janssen. All other authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13667"}}